Abstract
Liver fibrosis is a dynamic and highly integrated pathological process resulting from repeated liver injury healing accompanied by inflammation and extracellular matrix deposition. Treatment is necessary at the early stage of reversible liver fibrosis to prevent further deterioration to liver cirrhosis and liver cancer. Currently, the inhi-bition of liver fibrosis are mainly focused on prevention the activation of hepatic stellate cells and inhibition of inflammatory pathways involved in liver fibrosis. Previous research in our lab found that natural phenanthrenes derived from Traditional Chinese Medicine Baiyangjie could inhibit liver fibrosis through inhibiting TGF-131, TNF-alpha and promoting the secretion of MMP-9. Herein, in order to optimize the structure of phenanthrenes to maximize their anti-fibrosis activities, a series of phenanthrene derivatives were designed and synthesized in an expeditious manner. Their ability to inhibit LPS-initiated cellular liver fibrosis in HSC-T6 cells were examined and the results indicated that compounds A-1 and B-1 provided the best cellular anti-fibrosis activities. Further studies implied that they inhibited the LPS-initiated cellular liver fibrosis through inhibition the secretion of TNF-alpha, IL-113, TGF-131 and alpha-SMA. From these data, a picture emerges wherein a novel idea using phenanthrenes A-1 and B-1 as potential candidates to treat liver fibrosis for further animal studies.
NSTL
Elsevier